アブストラクト
| Title | 遅発性ジスキネジア |
|---|---|
| Subtitle | 連載 Medical Scope |
| Authors | 楠戸惠介*,**, 竹内啓善*,*** |
| Authors (kana) | |
| Organization | *慶應義塾大学医学部精神・神経科学教室, **国立病院機構千葉医療センター, ***(講師) |
| Journal | Pharma Medica |
| Volume | 39 |
| Number | 12 |
| Page | 59-65 |
| Year/Month | 2021 / 12 |
| Article | 報告 |
| Publisher | メディカルレビュー社 |
| Abstract | 「ABSTRACT」本稿では, まず, 遅発性ジスキネジア(tardive dyskinesia: TD)の定義, 分類, 診断基準と重症度評価について解説する. 最近のメタアナリシスでは, 第2世代抗精神病薬は第1世代抗精神病薬と比べてTDの有病率と発生率が低いこと, クロザピンへの切り替えによりTDが改善することが示されている. 抗精神病薬は用量依存的にTDを惹起するかどうかについては, 最近のレビューでは結論づけられないとしている. TDにおける危険因子として, 高齢, 女性, 人種, 遺伝子多型, 気分障害などがある. TDの発現機序はいまだ解明されていないが, 二大仮説であるドパミン受容体過感受性仮説と酸化ストレス仮説を中心に説明する. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982: 39: 486-7.
- 2) Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993; 50: 723-33.
- 3) Kane JM, Correll CU, Nierenberg AA, et al. Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop. J Clin Psychiatry. 2018; 79: 17cs11959.
- 4) Carbon M, Hsieh CH, Kane JM, et al. Tardive Dyskinesia Prevalence in the Period of Second-Gencration Antipsychotic Use: A Meta-Analysis. J Clin Psychiatry. 2017; 78: e264-78.
- 5) Carbon M, Kane JM, Leucht S, et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018; 17: 330-40.
残りの34件を表示する
- 6) Pardis P, Remington G, Panda R, et al. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review. J Psychopharmacol. 2019; 33: 1187-98.
- 7) Johnson CG, Littrell KH, Magill AM. Starting Patients on clozapine in a partial hospitalization program. Hosp Community Psychiatry. 1994; 45: 264-8.
- 8) Littrell K, Magill AM. The effect of clozapine on preexisting tardive dyskinesia. J Psychosoc Nurs Ment Health Serv. 1993; 31: 14-8.
- 9) Small JG, Milstein V, Marhenke JD, et al. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry. 1987; 48: 263-7.
- 10) Dalack GW, Becks L, Meador-Woodruff JH. Tardive dyskinesia, clozapine, and treatment response. Prog Neuropsychopharmacol Biol Psychiatry. 1998; 22: 567-73.
- 11) Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996; 53: 1090-7.
- 12) Moore NC, Lewitt PA, Gershon S. Reduction of dyskinesias and psychiatric disability with clozapine over different time courses. J Psychopharmacol. 1992; 6: 514-8.
- 13) Rosenheck R, Cramer J, Xu W, et al. A Comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997; 337: 809-15.
- 14) Nair CJ, Abraham G, Stanilla JK, et al. Therapeutic effects of clozapine on tardive dyskinesia. Cognitive and Behavioral Practice. 1998; 5: 123-31.
- 15) Simpson GM, Lee JH, Shrivastava RK. Clozapine in Tardive Dyskinesia. Psychopharmacology. 1978; 56: 75-80.
- 16) Li CR, Chung YC, Park TW, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J Biol Psychiatry. 2009; 10(4 Pt 3): 919-24.
- 17) Kane JM, Woerner MG, Pollack S, et al. Does Clozapine Cause Tardive Dyskinesia? J Clin Psychiatry. 1993; 54: 327-30.
- 18) Lin CC, Bai YM, Chen JY, et al. Switching from clozapine to zotepine in schizophrenic patients: A randomized, single-blind controlled study. Eur Neuropsychopharmacol. 2003; 4: S318-9.
- 19) Lin CC, Bai YM, Chen JY, et al. Treatment of clozapine-associated tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 599-600.
- 20) Mentzel TQ, van der Snoek R, Lieverse R, et al. Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis. J Clin Psychiatry. 2018; 79: 17r11852.
- 21) Solmi M, Pigato G, Kane JM, et al. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018; 389: 21-7.
- 22) Yoshida K, Takeuchi H. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. Behav Brain Res. 2021; 402: 113098.
- 23) Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013; 9: 1371-80.
- 24) Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. BMC Neurol. 2019; 19: 174.
- 25) Takeuchi H, MacKenzie NE, Samaroo D, et al. Antipsychotic Dose in Acute Schizophrenia: A Meta-Analysis. Schizophr Bull. 2000; 46: 1439-58.
- 26) Bergman H, Rathbone J, Agarwal V, et al. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2018; 2: CD000459.
- 27) Mentzel CL, Bakker PR, van Os J, et al. Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curacao Extrapyramidal Syndromes Study XII. J Clin Psychiatry. 2017; 78: e279-85.
- 28) Roongroj B, Jitkritsadakul O, Friedman JH, et al. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018; 389: 67-75.
- 29) 楠戸恵介, 竹内啓善. バルベナジンの作用機序, 有効性, 安全性(特集 不随意運動への対応). 精神科=Psychiatry. 2021 ; 38 : 486-94.
- 30) Cho CH, Lee HJ. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 46: 207-13.
- 31) Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry. 2008; 13: 544-56.
- 32) Zai CC, Tiwari AK, Basile V, et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1(NQO1) and Superoxide dismutase 2(SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34: 50-6.
- 33) Wang DF, Cao B, Xu MY, et al. Meta-Analyses of Manganese Superoxide Dismutase Activity, Gene Ala-9 Val Polymorphism, and the Risk of Schizophrenia. Medicine(Baltimore). 2015; 94: e1507.
- 34) Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012; 27: 1205-15.
- 35) Ananth J. Current psychopathological theories of tardive dyskinesia and their implications for future research. Neuropsychobiology. 1982; 8: 210-22.
- 36) Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005; 50: 541-7.
- 37) Sachdev P, Saharov T, Cathcart S. 1999. The preventative role of antioxidants(selegiline and vitamin E) in a rat model of tardive dyskinesia. Biol Psychiatry. 1999; 46: 1672-81.
- 38) Gittis AH, Leventhal DK, Fensterheim BA, et al. Selective inhibition of striatal fast-spiking interneurons causes dyskinesias. J Neurosci. 2011; 31: 15727-31.
- 39) Alabed S, Latifeh Y, Mohammad HA, et al. Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. Cochrane Database Sys Rev. 2018; 4: CD000203.
